Georgia's Online Cancer Information Center


back

Colon/Rectal Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Colon/Rectal Cancer
Cancer Type = Colon/Rectal Cancer
NCI ID Cancer Type Trial Name
There are currently 36 active Colon/Rectal Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
2.
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Cancer Type
Colon/Rectal Cancer
NCT ID
Protocol IDs
NCT02563002
3.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT06120075
Protocol IDs
ARC-27
NCI-2024-03901
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
4.
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Solid Tumor
NCT ID
NCT05726864
Protocol IDs
ELI-002-201
NCI-2023-01631
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
5.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
Emory University School of Medicine
Atlanta
6.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCT ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
7.
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05253651
Protocol IDs
SGNTUC-029
NCI-2022-07692
2021-002672-40
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
8.
A Study to Examine How Often (Every 5 Years or 10 Years) a Colonoscopy Should be Done in Participants Who Had One or Two Small Growths of Tissue Removed from Their Colon
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT05080673
Protocol IDs
NRG-CC005
NRG-CC005
NRG-CC005
NCI-2020-00733
9.
A Web-based Dyadic Intervention to Manage Psychoneurological Symptoms for Patients with Colorectal Cancer and Their Caregivers
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT05663203
Protocol IDs
STUDY00004750
NCI-2022-08788
EU5733-22
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
10.
NCORP Trial
An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCT ID
NCT06073431
Protocol IDs
URCC-22063
URCC-22063
URCC-22063
NCI-2023-04268
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
11.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
12.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
13.
NCORP Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02997228
Protocol IDs
NRG-GI004
NRG-GI004
NCI-2016-01961
NRG-GI004/S1610
Treatment Sites (4)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
14.
DECOY20 Study in Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCT ID
NCT05651022
Protocol IDs
INDP-D101
NCI-2022-10991
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
15.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
16.
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT03485209
Protocol IDs
SGNTV-001
NCI-2018-00676
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
17.
NCORP Trial
EHR Tool in Assessing Heart Health among Cancer Survivors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT03935282
Protocol IDs
WF-1804CD
WF-1804CD
WF-1804CD
NCI-2019-01362
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
18.
Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type
Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer
NCT ID
NCT05394428
Protocol IDs
20-2369
NCI-2022-05850
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
19.
Fiber-Rich Foods for the Treatment of Obesity and Prevention of Colon Cancer
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT04780477
Protocol IDs
RSPH5056-20
NCI-2020-04372
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
20.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03401385
Protocol IDs
DS1062-A-J101
NCI-2018-01200
173812
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
21.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
22.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT05047536
Protocol IDs
KZR-261-101
NCI-2022-01096
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
23.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03983993
Protocol IDs
Winship4517-18
NCI-2018-02757
IRB00107377
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
24.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type
Colon/Rectal Cancer, Sarcoma, Solid Tumor
NCT ID
NCT03715933
Protocol IDs
Ph1 INBRX-109
NCI-2018-03556
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
25.
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Melanoma, Ovarian Cancer
NCT ID
NCT05585034
Protocol IDs
XmAb808-01
NCI-2023-00610
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
26.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
27.
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCT ID
NCT05631574
Protocol IDs
COVALENT-102
NCI-2023-01290
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
28.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Cancer Type
Colon/Rectal Cancer, Gynecologic Cancers
NCT ID
NCT02628067
Protocol IDs
NCT02628067
3475-158
2015-002067-41
163196
Treatment Sites (3)
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
South Atlanta Hematology Oncology - Riverdale
Riverdale
29.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCT ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
30.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCT ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
31.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT05863195
Protocol IDs
EA2222
EA2222
NCI-2023-02357
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
32.
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) after Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05610163
Protocol IDs
A022104
A022104
NCI-2022-07800
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
33.
Testing the Addition of Nivolumab to Standard Treatment for Patients with Metastatic or Unresectable Colorectal Cancer that have a BRAF Mutation
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05308446
Protocol IDs
S2107
S2107
NCI-2022-02494
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
34.
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05673148
Protocol IDs
A022101
A022101
NCI-2022-09253
Treatment Sites (1)
Emory Proton Therapy Center
Atlanta
35.
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05710406
Protocol IDs
A022004
A022004
NCI-2022-09129
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
36.
NCORP Trial
Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05174169
Protocol IDs
NRG-GI008
NRG-GI008
NCI-2021-08397
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Columbus Regional
Columbus
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.